Biotech Startup ai3Bio Emerged With $48 Million
The Massachusetts-based firm aims to treat autoimmune diseases by clearing dysregulated T cells starting in 2027.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust that new medical technologies will effectively manage autoimmune conditions for patients?
Biotech startup ai3Bio launched from stealth today with $48 million in new funding. The company, formed from a merger of Corner Therapeutics and Novasenta, focuses on removing diseased cells involved in chronic inflammation.
Why it matters
Th17-expressing T cells are often dysregulated in autoimmune conditions, driving persistent tissue damage and inflammation. Addressing these cells directly represents a targeted approach to managing chronic disease progression.
The startup's StarX platform utilizes lipid nanoparticles — microscopic fat-based delivery vehicles — to deliver mRNA payloads to CD161-expressing cells. This process triggers apoptosis, or programmed cell death, via the cGAS-STING signaling pathway.
The players
ai3Bio
A Massachusetts-based biotech startup focused on T cell targeting through its StarX and T Deplete platforms.
UPMC Enterprises
The commercialization arm of the University of Pittsburgh Medical Center that invests in health-tech and biotech ventures.
Ziff Capital Partners
An investment firm that led the current funding round for the startup.
The details
The StarX platform delivers mRNA that causes targeted Th17 cells to destroy themselves through the cGAS-STING pathway, a component of the innate immune system. Separately, the firm's T Deplete platform employs a targeting antibody to flag diseased cells for clearance by recruited immune cells. These methods focus on removing specific cell populations known to exacerbate chronic inflammation.
Timeline
September 29, 2026: ai3Bio emerged from stealth.
June 2025: AbbVie invested $2.1 billion in Capstan Therapeutics.
October 2025: Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion.
2027 or 2028: Target date for moving assets to clinical trials.
The Tech Race
The launch of ai3Bio reflects a broader industry push to deploy advanced delivery systems for immune-cell modulation. The firm enters a crowded landscape defined by multi-billion dollar deals, such as the 2025 acquisitions of Orbital Therapeutics and Capstan Therapeutics.
The firm is currently in its initial fundraising phase and does not yet have products available for patients. Clinical relevance remains subject to the company successfully moving its assets into human trials, a milestone currently projected for 2027 or 2028.
The takeaway
The company is positioning itself to address autoimmune disease through cell-specific elimination. Readers should monitor the startup's progress toward its 2027 clinical milestone for evidence of the platform's efficacy in human models.
Further reading
Explore more developments in the field at Biotech.
Live Poll
Do you trust that new medical technologies will effectively manage autoimmune conditions for patients?
